anti-b1 antibody
mAbexperimentalADC
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 1998 (NCT00022958)
Timeline
Indications
Mechanism of action
- Fibronectin receptor betaINHIBITOR
ITGB1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 131-iodine
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-b1 antibody
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00022945 | Phase 2 | Aug 16, 2001 | Corixa |
| NCT00022893 | N/A | Aug 15, 2001 | Corixa, GlaxoSmithKline |
| NCT00022932 | Phase 2 | Jan 1, 2000 | Corixa |
| NCT00022880 | Phase 1 | Jul 1, 1999 | Corixa, GlaxoSmithKline |
| NCT00022906 | Phase 1 | May 1, 1999 | Corixa, GlaxoSmithKline |
| NCT00992758 | Phase 1 | May 1, 1999 | GlaxoSmithKline |
| NCT00022958 | N/A | Sep 1, 1998 | Corixa, GlaxoSmithKline |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Corixa | For profit | 6 | 6 | 3 | 1998 |
| GlaxoSmithKline | For profit | 5 | 1 | 2 | 1998 |
2 organizations
Page 1 / 1